Abstract
Nonalcoholic fatty liver disease (NAFLD) is closely related to glycolipid metabolism and liver inflammation. And there is no effective drug approved for its clinical therapy. In this study, we focused on mangiferin (Man) and explored its effects and mechanisms on NAFLD treatment based on the regulation of glycolipid metabolism and anti-inflammatory in vivo and in vitro. The results exhibited that Man can significantly attenuate liver injury, insulin resistance, and glucose tolerance in high-fat diet- (HFD-) induced NAFLD mice and significantly reduce fat accumulation and inflammation in hepatic tissue of NAFLD mice. The transcriptome level RNA-seq analysis showed that the significantly different expression genes between the Man treatment group and the HFD-induced NAFLD model group were mainly related to regulation of energy, metabolism, and inflammation in liver tissue. Furthermore, western blots, real-time PCR, and immunohistochemistry experiments confirmed that Man significantly activated the AMPK signal pathway and inhibited NLRP3 inflammasome activation and pyroptosis in NAFLD mice. In in vitro cell experiments, we further confirmed that Man can promote glucose consumption and reduce intracellular triglyceride (TG) accumulation induced by free fatty acids in HepG2 cells and further that it can be blocked by AMPK-specific inhibitors. Western blot results showed that Man upregulated p-AMPKα levels and exhibited a significant AMPK activation effect, which was blocked by compound C. At the same time, Man downregulated the expression of NLRP3 inflammasome-related proteins and inhibited the activation of NLRP3 inflammasome, alleviating cell pyroptosis and inflammation effects. These results indicate that Man anti-NAFLD activity is mediated through its regulation of glucolipid metabolism by AMPK activation and its anti-inflammatory effects by NLRP3 inflammasome inhibition. Our study indicates that Man is a promising prodrug for the therapy of NAFLD patients.
Highlights
As we know, excessive lipid accumulation and steatosis in hepatocytes are the two main characters for nonalcoholic fatty liver disease (NAFLD) patient [1]
We study on the effects of Man in the prevention and treatment of NAFLD and explore its mechanisms of glycolipid metabolism regulation and its anti-inflammatory activity based on the AMPK and NLRP3 inflammasome signal pathways
We further evaluate the intracellular lipid accumulation induced by palmitic acid (PA)-bovine serum albumin (BSA) in hepatocyte by Oil Red O (ORO) staining
Summary
Excessive lipid accumulation and steatosis in hepatocytes are the two main characters for nonalcoholic fatty liver disease (NAFLD) patient [1]. NAFLD, as the most commonly liver-related disease, includes simple fatty liver, steatohepatitis, fibrosis, cirrhosis, and even hepatocellular carcinoma [2], which causes a huge human health challenge and global medical burden [3]. With continuous exploration and scientific improvement, the proposed pathogenesis of NAFLD has developed from the “two hit” theory to the “multiple parallel hits” hypothesis, which includes factors such as fat accumulation, lipotoxicity, oxidative stress, inflammation, insulin resistance, endoplasmic reticulum stress, and mitochondrial dysfunction [4,5,6]. Liver glucose and lipid metabolic disorder and inflammation are the most common initial predisposing factors for NAFLD development [7]. Discovering and investigating effective therapeutic drugs for NAFLD is an urgent problem worldwide
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.